Detailed price information for Ferrari N.V. (RACE-N) from The Globe and Mail including charting and trades.
HeartBeam Inc (BEAT) advances its 510(k) heart attack detection pathway with strong ALIGN ACS results and extended runway into 2027, while Nasdaq compliance and pivotal study timing remain key risks.
SANTA CLARA, Calif., November 02, 2026--HeartBeam Announces Positive Heart Attack Pilot Study Results at TCT 2026: Patient-Recorded 3D ECG Shown to be as Accurate as Standard 12-Lead ECG
HeartBeam secures an expedited FDA designation for its 3D ECG at-home heart attack assessment tool, paving the way for rapid clinical trials.
Gainers HeartBeam (NASDAQ:BEAT) stock moved upwards by 70.5% to $0.74 during Monday's regular session. The market value of their outstanding shares is at $24.4 million. PDS Biotechnology (NASDAQ:PDSB) shares moved
The designation gives HeartBeam prioritized FDA interaction as it prepares a pivotal study of its 3D ECG technology for assessing suspected heart attacks outside traditional medical settings. Key Investor TakeawaysHeartBeam (NASDAQ:BEAT) received FDA Breakthrough Device Designation for using its 3D ECG technology to assess potential heart attacks at home.
SANTA CLARA, Calif., September 21, 2026--HeartBeam, Inc. Letter to Shareholders
This is the newest page. Registered accounts read further back.